Signos announced that it raised $20 million in a Series B round to support its AI-powered continuous glucose monitor (CGM) technology.
San Francisco-based Signos develops a comprehensive metabolic health platform. It includes a proprietary AI engine with a CGM to provide real-time data and recommendations for weight management. Signos aims for its metabolic-led solution to reverse prediabetes and aid those on their weight loss journey.
Previously only available for non-diabetics, the company expanded its platform to support people with type 2 diabetes earlier this year.
The company says its new funding round helps it expand its core team and platform, plus conduct additional research. Cheyenne Ventures and Google Ventures led the round, while Dexcom Ventures and Samsung Next also contributed.
Signos’ app enables members to log what they eat and how much they exercise. It enables the AI platform to learn how a metabolism reacts to different foods and fitness patterns. The offering then provides data-driven, personalized recommendations based on an individual’s unique metabolic profile.
“Sleep, stress, exercise, and diet all influence how high and sustained one’s glucose spikes can be,” CEO Sharam Fouladgar-Mercer said. “We often don’t realize that people make around 227 food-related decisions a day. By providing glucose visibility, tracking, and AI-driven proactive suggestions, Signos can help you navigate those choices for better health.”